Gain Therapeutics spikes after lab data on Parkinson’s Disease candidate

Apr. 12, 2022 1:27 PM ETGain Therapeutics, Inc. (GANX)By: Dulan Lokuwithana, SA News Editor

On the table are a stethoscope, a thermometer, a pen and a notebook with the inscription -Parkinsons disease

Dzmitry Skazau/iStock via Getty Images

  • The shares of Gain Therapeutics (NASDAQ:GANX) quickly surged, triggering a trading halt on volatility after the development-stage biotech presented pre-clinical data from its Parkinson’s Disease (PD) program for the lead asset GT-02287.
  • According to the results highlighted at a medical event in Belgium, GT-02287 was found to improve neuronal network connections and neuron survival in PD, Gain (GANX) said.
  • In addition, the data shows that the oral candidate increases the levels and activity of the lysosomal enzyme GCase, which represents a common hereditary risk factor for the disease, and “improves lysosomal health, corrects abnormal phenotypes of PD including alpha-synuclein.”
  • The data were based on certain in vitro models with mutations of the GBA1 gene, which encodes the GCase enzyme.
  • Read: In March, Gain (GANX) said that it expected to submit regulatory filings in Australia to start a first-in-human Phase 1 clinical trial in GBA1 PD.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.